ARMS - Administration Of Rapidly Generated Multivirus-Specific Cytotoxic T-Lymphocytes For The Prophylaxis And Treatment Of EBV, CMV, Adenovirus, HHV6, And BK Virus Infections Post Allogeneic Stem Cell Transplant

Trial Profile

ARMS - Administration Of Rapidly Generated Multivirus-Specific Cytotoxic T-Lymphocytes For The Prophylaxis And Treatment Of EBV, CMV, Adenovirus, HHV6, And BK Virus Infections Post Allogeneic Stem Cell Transplant

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Cytotoxic T lymphocytes ViraCyte (Primary)
  • Indications Viral infections
  • Focus Adverse reactions
  • Acronyms ARMS
  • Sponsors ViraCyte
  • Most Recent Events

    • 05 Jul 2017 Planned End Date changed from 1 Dec 2016 to 1 Jan 2020.
    • 05 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 23 May 2017 Planned number of patients changed from 35 to 43.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top